

Cite this: *Chem. Sci.*, 2020, **11**, 11531

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 11th July 2020

Accepted 30th September 2020

DOI: 10.1039/d0sc03791e

rsc.li/chemical-science

Site-selective aqueous C–H acylation of tyrosine-containing oligopeptides with aldehydes†

Marcos San Segundo and Arkaitz Correa *

The development of useful synthetic tools to label amino acids within a peptide framework for the ultimate modification of proteins in a late-stage fashion is a challenging task of utmost importance within chemical biology. Herein, we report the first Pd-catalyzed C–H acylation of a collection of Tyr-containing peptides with aldehydes. This water-compatible tagging technique is distinguished by its site-specificity, scalability and full tolerance of sensitive functional groups. Remarkably, it provides straightforward access to a high number of oligopeptides with altered side-chain topology including mimetics of endomorphin-2 and neuromedin N, thus illustrating its promising perspectives toward the diversification of structurally complex peptides and chemical ligation.

Introduction

Non-natural amino acids and peptides derived thereof are highly coveted compounds in proteomics and drug discovery due to their often enhanced biological activities and improved metabolic stability compared with their native analogues.¹ As a result, there is an urgent demand to increase the available synthetic toolbox to perform chemical labelling processes of peptides and proteins in a late-stage fashion. Innovation is occurring at a rapid pace and a myriad of reliable methods have emerged within the last decade in the burgeoning area of bio-conjugation.² Metal catalysis has recently unlocked new tactics in the field,³ thereby enabling the development of a sheer number of metal-catalyzed modification techniques featuring the manipulation of otherwise unreactive C–H bonds embedded within the amino acid backbone⁴ and the corresponding side-chains.⁵ The latter have streamlined the straightforward assembly of biomolecules of paramount significance in a more sustainable manner by avoiding the use of pre-functionalized substrates. Despite the wealth of reports in the field, several challenges still remain: (a) most of the protocols entailed the diversification of a limited number of amino acid residues including tryptophan (Trp), glycine (Gly), alanine (Ala), cysteine (Cys) or phenylalanine (Phe), among others,⁶ and (b) toxic halide-counterparts and organic solvents are usually required. Accordingly, the selective tagging of other canonical amino acid residues while implementing atom-economical C–H coupling partners represents an unmet

challenge of capital significance within peptide chemistry and protein engineering.

Tyrosine (Tyr), the 4-hydroxylated congener of Phe, constitutes an abundant proteinogenic amino acid, which is a privileged core in a vast array of relevant compounds such as neurotransmitters and hormones, as well as a versatile precursor to numerous alkaloids with potent antibiotic activity such as vancomycin, among others (Fig. 1).⁷

Likewise, Tyr-containing compounds are of widespread use as dietary supplements or food additives, and play a pivotal role in biological processes such as photosynthesis. Its inherent chemical reactivity is dictated by the pH-tunable and electron-rich phenol-containing side-chain. In this regard, several transformations performed in simple phenols have been translated into elegant tagging techniques of Tyr-containing





Fig. 1 Illustrative Tyr-containing biologically relevant polypeptides.

University of the Basque Country (UPV/EHU), Department of Organic Chemistry I, Joxe Mari Korta R&D Center, Avda. Tolosa 72, 20018 Donostia-San Sebastián, Spain. E-mail: arkaitz.correa@ehu.eus

† Electronic supplementary information (ESI) available: Experimental procedures, data for new compounds, ¹H, ¹³C and ¹⁹F NMR spectra. See DOI: 10.1039/d0sc03791e

Scheme 1 *Ortho* C–H functionalization of Tyr derivatives.Table 1 Pd-catalyzed C(sp²)-H acylation of dipeptide **1a** with **2a**^a

1a + *p*-anisaldehyde (3.0 equiv.)
Pd(OAc)₂ (10 mol %), TBHPaq (4.0 equiv.), H₂O (0.2 M), 90 °C, 16 h
3aa, R = H
3'aa, R = CO(PMP)

Entry	Change from standard conditions	3aa ^b (%)
1	None	78 (8 : 2) ^c
2	Without Pd(OAc) ₂	0
3	Without TBHPaq	0
4	Under air	46 (93 : 7)
5	Under O ₂	0
6	With 2.0 equiv. of TBHPaq	65 (93 : 7) ^c
7	6.0 equiv. of 2a	88 (6 : 4) ^c
8	(NH ₄) ₂ S ₂ O ₈ instead of TBHPaq	Traces
9	DTBP instead of TBHPaq	Traces
10	H ₂ O ₂ instead of TBHPaq	Traces
11	^t BuOOBz instead of TBHPaq	33 (7 : 3) ^c
12	DCP instead of TBHPaq	Traces

^a Reaction conditions: **1a** (0.15 mmol), **2a** (0.45 mmol), Pd(OAc)₂ (10 mol%), TBHPaq (4.0 equiv.) in H₂O (0.75 mL) at 90 °C for 16 h under Ar. ^b Yield of isolated product after column chromatography. ^c Ratio of mono- and diacylated product (**3aa** : **3'aa**). DTBP = di-*tert*-butyl peroxide; DCP = dicumyl peroxide; TBHPaq (Luperox®, 70 wt% in water).

peptides. Whereas *O*-functionalization reactions including arylation,⁸ alkylation⁹ and glycosylation¹⁰ reactions generally occur under basic conditions, *C*-targeted reactions at the *ortho*-C–H bond to the phenol motif usually proceed in acidic or neutral conditions. The introduction of highly reactive electrophiles upon Mannich-type reactions,¹¹ diazonium couplings¹² or ene-type reactions¹³ as well as *N*-centered radicals derived from

phenothiazines¹⁴ has been achieved under metal-free reaction conditions. Conversely, metal catalysis has been crucial to install other coupling partners such as aryl halides,¹⁵ aryl trifluoroborate salts,¹⁶ acrylates¹⁷ and the trifluoromethyl group¹⁸ (Scheme 1, route a). The latter have been rarely applied within a challenging peptide framework and hence the site-selective modification of tyrosine unit still remains elusive.


As part of our interest in the radical modification of peptides,¹⁹ we have recently reported unprecedented Pd-catalyzed C–H acylation reactions for the efficient labelling of Phe-containing peptides.²⁰ While conceptually innovative, the protocol suffered from certain downsides such as the requirement of stoichiometric amounts of silver salts to ensure high yields,²¹ the use of DMF as toxic organic solvent and it was found just applicable to Phe derivatives housing a picolinamide as directing group (DG) at the *N*-terminal position. Given that the use of aldehydes has been overlooked in the realm of bio-conjugation, we sought to unveil their full synthetic potential in the virtually unexplored *ortho*-C–H acylation of Tyr residues within complex peptide settings. Building on precedents in C–H acylation reactions,²² we predicted that the use of a DG would be determinant for achieving site-selectivity²³ through the formation of a 6-membered palladacycle prone to undergo further oxidative addition of the transient acyl radical species (Scheme 1, route b). In particular, we envisioned that the conversion of the native Tyr unit into the corresponding 2-pyridyl ether compound²⁴ would be crucial to enable the site-selective modification of Tyr residues at any position within the peptide sequence. Herein we report on the first Pd-catalyzed C–H acylation of Tyr-containing peptides with aldehydes. This scalable method avoids the undesired use of toxic and expensive silver salts, and features the use of water as a non-flammable and environmentally-friendly solvent, thus resulting in a powerful diversification technique of paramount importance in peptide chemistry.

Results and discussion

We commenced our studies by exploring the radical acylation of Boc-Tyr(OPy)-Leu-OMe (**1a**) with *p*-anisaldehyde (**2a**) as the model reaction. When submitting dipeptide **1a** to the previously reported reaction conditions for the acylation of Phe-containing peptides²⁰ just traces of **3aa** were obtained, hence showing the subtleties of the modification of the Tyr scaffold. Initial exploratory solvent screening with *tert*-butyl hydroperoxide (TBHP) as oxidant showed the feasibility of our approach and moderate to good yields were obtained in solvents such as toluene, acetonitrile, chlorobenzene and even water (Table S1†).²⁵ Driven by its clear benefits in the modification of biomolecules, we focused on the development of a practical acylation under an aqueous environment.²⁶

After considerable experimentation,²⁵ we eventually found that the combination of Pd(OAc)₂ (10 mol%), an aqueous solution of inexpensive TBHP (Luperox®) as oxidant in neat water as solvent at 90 °C provided **3aa** in 78% yield as a mixture of mono- and diacylated products (8 : 2 ratio) (entry 1). Blank experiments underpinned the crucial role of both Pd catalyst



Table 2 Pd-catalyzed C(sp²)-H acylation of Tyr-containing dipeptide **1a** with aldehydes^{a,b}

^a As for Table 1, entry 1. ^b Yield of isolated product after column chromatography, average of at least two independent runs. ^c Ratio of mono- and diacylated product (**3** : **3'**). ^d Gram scale experiment. ^e Reaction performed in toluene. ^f Reaction performed in PhCl with 5.0 equiv. of aldehyde. ^g Reaction performed in toluene at 100 °C with 5.0 equiv. of aldehyde.


and oxidant in the acylation reaction as not even traces of **3aa** were detected in their absence (entries 2 and 3, respectively). The performance of the reaction under air resulted in lower yields of **3aa** (entry 4) and the process was entirely inhibited under an oxygen atmosphere (entry 5). The use of variable amounts of oxidant and *p*-anisaldehyde led to an optimal balance between yield and mono-selectivity when using 4.0 and 3.0 equivalents, respectively. For example, when using 2.0 equivalents of TBHP, **3aa** was obtained in a comparatively lower yield (entry 6) and when increasing the amount of aldehyde to 6.0 equivalents the higher yield was due to a loss in regioselectivity (entry 7). Other reaction parameters such as palladium source, supporting ligands and reaction temperature were analyzed but lower yields were obtained; indeed, higher selectivity toward the monoacylation product was only achieved at the expense of obtaining lower overall yields.²⁵

As depicted on Table 1, an aqueous solution of TBHP provided much better results than other related peroxides or persulfates (entries 8–12), which together with the use of water as solvent constitutes an additional bonus of the method in terms of economics and sustainability. Importantly, unlike other Pd-catalyzed C–H peptide modification reactions, silver additives were found to be unnecessary. Moreover, despite the highly oxidizing reaction system, undesired *N*-acylation of the peptide backbone with *p*-anisaldehyde was never observed.²⁷

With the optimized conditions in hand, we next investigated the scope of the C(sp²)-H acylation protocol with Tyr-containing dipeptide **1a**. Notably, a wide variety of electronically diverse

aldehydes smoothly underwent the target oxidative coupling, thus enabling the rapid access to a variety of unknown acylated Tyr-containing dipeptides in a late-stage manner. In general, a variety of benzaldehydes regardless of their electronic nature provided the corresponding acylated products **3** in good yields as mixtures of mono- and diacylated compounds, with a preferential selectivity toward the monoacylated product (up to 8 : 2 ratio). The method was compatible with the presence of ethers (**3aa–ad**), halides (**3ae–ah**), acetamide (**3ai**) and naphthyl system (**3ak**). Conversely, the highly electron-withdrawing nitro group resulted in no conversion of dipeptide **1a**. Interestingly, the lower tendency to oxidation of aliphatic aldehydes such as heptanal and cyclohexanecarboxaldehyde ushered in the exclusive formation of mono-acylated products **3am** and **3an**, respectively, in moderate yields under the standard reaction conditions featuring the use of water as the sole solvent. However, the performance of the process in chlorobenzene with a higher excess of the corresponding aldehydes resulted in slightly higher yields (up to 57%). Likewise, other challenging aldehydes housing pharmaceutically relevant heterocyclic scaffolds could be also employed as reaction partners, although the use of toluene as solvent at 100 °C was found determinant for the process to occur.²⁵ Accordingly, 2-thiophene (**2o**), 2-furan (**2p**), *N*-methyl-2-pyrrole (**2m**) and *N*-methyl-3-indolyl carboxaldehydes (**2n**) selectively afforded the corresponding mono-acylated products **3ao–ar**. It is noteworthy that a gram-scale acylation with *p*-(trifluoromethyl)benzaldehyde (**2h**) was successfully performed, which verified the robustness and



Table 3 Pd-catalyzed C(sp²)-H arylation of Tyr-containing oligopeptides with aldehydes^{a,b}

^a As for Table 1, entry 1. ^b Yield of isolated product after column chromatography, average of at least two independent runs. ^c Ratio of mono- and diacylated product (3 : 3'). ^d Using toluene as solvent.


synthetic utility of our peptide tagging manifold. Collectively, the aqueous acylation of Tyr derivatives reported herein underscores related protocols on simple 2-phenoxyphenyl derivatives, which occurred at higher reaction temperatures (up to 140 °C), in chlorinated solvents and are restricted to the use of benzaldehydes (Table 2).^{24b,g}

We next explored the synthetic scope in the challenging setting of short-to-medium size peptides (Table 3). Notably, peptides bearing Phe (**1b**), Val (**1c**), Gly (**1d**), Asn (**1e**), Ser (**1f**), Asp (**1g**), non-protected Tyr (**1h**), Pro (**1i**), Ala (**1j**), and Lys (**1k**)

boded well with the reaction conditions and provided the corresponding acylated dipeptides (**3b-k**) in good yields. The success of the method did not rely on a specific situation of the Tyr along the peptide sequence, and was applicable to Tyr residues located both at the *N*- and *C*-terminal positions.

We next evaluated the viability of the Pd-catalyzed acylation for the late-stage diversification of more complex oligopeptides. In this respect, the process efficiently occurred in a selective manner in Tyr-containing tri- and tetrapeptides (**1l-o**), including even peptides housing the Tyr unit in inner positions




Scheme 2 Consecutive C(sp²)–H arylation reaction.

(1m,n). Importantly, pentapeptide **1p** and hexapeptide **1q** bearing the amino acid sequence of biologically relevant Endomorphin-2 and Neuromedin N, respectively, were also acylated in a late-stage fashion. The latter examples illustrate the high synthetic potential of this acylation technique toward the site-selective labelling of biomolecules of high structural complexity. In all cases, the incorporation of the radical acyl species was biased by the 2-pyridyloxy group attached to the phenol ring within the Tyr residue and other sensitive functional groups such as carboxamides within Gln (**3nh**) and Asn (**3eh**) as well as oxidizable protic free-hydroxyl groups of Ser (**3fh**) and Tyr (**3ha**) remained intact under the reaction conditions. The free-amino group of Lys residue (**3ka**, **3qh**) as well as

the *N*-terminal residue of the peptide sequence was conveniently protected to avoid undesired oxidative aminations with the corresponding aldehyde.²⁸ Peptides bearing other electron-rich aromatic residues such as His and Trp or guanidine-containing Arg unit were not tolerated.²⁵ Likewise, thiol-containing Cys and Met residues were not accommodated, which could be due to competitive oxidative reactions with the corresponding aldehydes (Table S8, ESI†).²⁹

With the aim to create molecular diversity, we extended the scope beyond the introduction of one single aldehyde into the Tyr unit, and found that the performance of two consecutive arylation reactions with two distinct benzaldehydes enabled the assembly of fully decorated Tyr-containing dipeptide **3as** in a selective manner (Scheme 2).


Likewise, the aldehyde unit could be tethered within a Tyr-containing peptide and efficiently coupled with another Tyr-containing short-to-medium peptide to deliver unprecedented oligopeptides featuring a unique diaryl ketone cross-linking (Table 4). Notably, the functionalization always occurred in a selective fashion toward the mono-acylated compounds. The practicality of the method within the realm of chemical ligation was verified by the selective mono-acylation of Neuromedin N analogue **1q**, thereby enabling the assembly of octapeptide **3qt** of high structural complexity. It must be noted that all the

Table 4 Pd-catalyzed C–H acylation toward chemical ligation^{a,b}

^a Reaction conditions: **1** (0.15 mmol), **2** (0.45 mmol), Pd(OAc)₂ (10 mol%), Luperox® (4.0 equiv.) in toluene (0.75 mL) at 90 °C for 16 h under Ar.

^b Yield of isolated product after column chromatography, average of at least two independent runs.





Scheme 3 Reductive cleavage of the DG.

experiments were run at least twice with a variable yield by no more than 5% between runs, thus showing the reliability of the protocol.

Although the facile removal of the OPy group has been customarily described in simple aryl systems upon a two-step sequence entailing *N*-methylation with methyl triflate followed by the cleavage of the resulting C(pyridinium)–O bond by treatment with an alcoholic solution of sodium,²⁴ its application in a peptide sequence resulted in mixtures of products and racemization of the existing chiral centers. Accordingly, we studied the use of modern metal-catalyzed borylation reactions for the ultimate, yet milder removal of the directing group.³⁰ After careful evaluation of a number of Rh-, Ni- and Fe-catalyzed borylation reactions, the targeted borylative cleavage was never achieved within our Tyr-containing peptides and the removal of the OPy group occurred in moderate yield to produce the corresponding reduced product 4.^{30b} Although it poses a limitation at first sight and remains an issue to be improved, further optimization of the process could provide a complementary avenue for the assembly of *meta*-arylated Phe-containing peptides, thereby resulting in the direct conversion of a Tyr residue into the Phe analogue featuring the use of the OPy as a traceless directing group (Scheme 3). Likewise, the fully decorated Tyr(OPy)-containing peptides assembled herein could offer interesting possibilities within drug discovery.

Conclusions

In summary, we have developed a broadly applicable method for the site-selective tagging of Tyr-containing oligopeptides featuring a novel Pd-catalyzed C(sp²)–H acylation reaction with abundant aldehydes. This labelling platform represents a reliable, yet innovative, means for the radical diversification of a wide variety of Tyr-containing compounds, thus providing access to novel peptidomimetics of high structural complexity. Although one might anticipate that site-selectivity issues might come into play in the presence of multiple C–H bonds, our work meets this challenge, offering an unrecognized opportunity within the radical labelling of peptides. Salient features of our protocol are the compatibility with an aqueous environment, the widespread availability and low-cost of the aldehydes, the broad functional group tolerance, the preferential site-selectivity toward the functionalization of the Tyr unit and the facile installation and removal of the required 2-pyridyl ether group. Accordingly, we anticipate that this Pd-catalyzed oxidative acylation manifold could become a useful synthetic tool for

the late-stage and rapid modification of a virtually unlimited set of Tyr-containing lead drug candidates.

Conflicts of interest

A patent disclosing the Pd-catalyzed aqueous acylation of Tyr-containing oligopeptides has been filed (P202030131, Spain).

Acknowledgements

We are grateful to Ministerio de Ciencia e Innovación (RTI2018-093721-B-I00, MCI/AEI/FEDER, UE) and Basque Government (IT1033-16) for financial support. We thank for technical and human support provided by Central Service of Analysis-SGIker of UPV/EHU and European funding (ERDF and ESF).

Notes and references

- (a) E. Lenci and A. Trabocchi, *Chem. Soc. Rev.*, 2020, **49**, 3262; (b) R. J. Malonis, J. R. Lai and O. Vergnolle, *Chem. Rev.*, 2020, **120**, 3210; (c) J. L. Lau and M. K. Dunn, *Bioorg. Med. Chem.*, 2018, **26**, 2700; (d) A. Henninot, J. C. Collins and J. M. Nuss, *J. Med. Chem.*, 2018, **61**, 1382.
- (a) J. N. deGruyter, L. R. Malins and P. S. Baran, *Biochemistry*, 2017, **56**, 3863; (b) N. Krall, F. P. da Cruz, O. Boutureira and G. J. L. Bernardes, *Nat. Chem.*, 2016, **8**, 102; (c) O. Koniev and A. Wagner, *Chem. Soc. Rev.*, 2015, **44**, 5495; (d) M. Pelay-Gimeno, A. Glas, O. Koch and T. N. Grossmann, *Angew. Chem., Int. Ed.*, 2015, **54**, 8896.
- (a) J. Ohata, S. C. Martin and Z. T. Ball, *Angew. Chem., Int. Ed.*, 2019, **58**, 6176; (b) P. G. Isenegger and B. G. Davis, *J. Am. Chem. Soc.*, 2019, **141**, 8005; (c) M. Jbara, S. K. Maity and A. Brik, *Angew. Chem., Int. Ed.*, 2017, **56**, 10644.
- (a) M. San Segundo and A. Correa, *Synthesis*, 2018, **50**, 2853; (b) T. Brandhofer and O. García Mancheño, *Eur. J. Org. Chem.*, 2018, 6050.
- For recent reviews, see: (a) I. Guerrero and A. Correa, *Asian J. Org. Chem.*, 2020, **9**, 898; (b) H. Grubbs and N. Sewald, *Chem.–Eur. J.*, 2020, **26**, 5328; (c) D. G. Rivera, G. M. Ojeda-Carralero, L. Reguera and E. V. Van der Eycken, *Chem. Soc. Rev.*, 2020, **49**, 2039; (d) Z. Bai and H. Wang, *Synlett*, 2020, **31**, 199; (e) C. Bottecchia and T. Noël, *Chem.–Eur. J.*, 2019, **25**, 26; (f) W. Wang, M. M. Lorion, J. Shah, A. R. Kapdi and L. Ackermann, *Angew. Chem., Int. Ed.*, 2018, **57**, 14700; (g) L. R. Malins, *Pept. Sci.*, 2018, **110**, e24049; (h) X. Lu, S.-J. He, W.-M. Cheng and J. Shi, *Chin. Chem. Lett.*, 2018, **29**, 1001; (i) S. Mondal and S. Chowdhury, *Adv. Synth. Catal.*, 2018, **360**, 1884; (j) L. R. Malins, *Curr. Opin. Chem. Biol.*, 2018, **46**, 25; (k) G. He, B. Wang, W. A. Nack and G. Chen, *Acc. Chem. Res.*, 2016, **49**, 635; (l) A. M. Metz and M. C. Kozlowski, *J. Org. Chem.*, 2015, **80**, 1; (m) A. F. M. Noisier and M. A. Brimble, *Chem. Rev.*, 2014, **114**, 8775.
- For a selection of recent examples, see: (a) L. Liu, Y.-H. Liu and B.-F. Shi, *Chem. Sci.*, 2020, **11**, 290; (b) J. Peng, C. Li, M. Khamrakulov, J. Wang and H. Liu, *Org. Lett.*, 2020, **22**, 1535; (c) X. Chen, F. Ye, X. Luo, X. Liu, J. Zhao, S. Wang,



- Q. Zhou, G. Chen and P. Wang, *J. Am. Chem. Soc.*, 2019, **141**, 18230; (d) S. Guin, P. Dolui, X. Zhang, S. Paul, V. K. Singh, S. Pradhan, H. B. Chandrashekar, S. S. Anjana, R. S. Paton and D. Maiti, *Angew. Chem., Int. Ed.*, 2019, **58**, 5633; (e) N. Kaplaneris, T. Rogge, R. Yin, H. Wang, G. Sirvinskaite and L. Ackermann, *Angew. Chem., Int. Ed.*, 2019, **58**, 3476; (f) M. J. Terrey, C. C. Perry and W. B. Cross, *Org. Lett.*, 2019, **21**, 104; (g) B.-B. Zhan, Y. Li, J.-W. Xu, X.-L. Nie, J. Fan, L. Jin and B.-F. Shi, *Angew. Chem., Int. Ed.*, 2018, **57**, 5858; (h) W. Wang, M. M. Lorion, O. Martinazzoli and L. Ackermann, *Angew. Chem., Int. Ed.*, 2018, **57**, 10554; (i) Y. Yu, L.-K. Zhang, A. V. Buevich, G. Li, H. Tang, P. Vachal, S. L. Colletti and Z.-C. Shi, *J. Am. Chem. Soc.*, 2018, **140**, 6797; (j) M. Bauer, W. Wang, M. M. Lorion, C. Dong and L. Ackermann, *Angew. Chem., Int. Ed.*, 2018, **57**, 203; (k) T. Liu, J. X. Qiao, M. A. Poss and J.-Q. Yu, *Angew. Chem., Int. Ed.*, 2017, **56**, 10924; (l) A. F. M. Noisier, J. García, I. A. Ionut and F. Albericio, *Angew. Chem., Int. Ed.*, 2017, **56**, 314; (m) G. Liao, X.-S. Yin, K. Chen, S.-Q. Zhang and B.-F. Shi, *Nat. Commun.*, 2016, **7**, 12901; (n) K. Li, Q. Wu, J. Lan and J. You, *Nat. Commun.*, 2015, **6**, 8404; (o) J. He, S. Li, Y. Deng, H. Fu, B. N. Laforteza, J. E. Spangler, A. Homs and J.-Q. Yu, *Science*, 2014, **343**, 1216.
- 7 (a) J. Lee, M. Ju, O. H. Cho, Y. Kim and K. Tae, *Adv. Sci.*, 2019, **6**, 1801255; (b) C. A. Schenck and H. A. Maeda, *Phytochemistry*, 2018, **149**, 82; (c) F. Albericio and H. G. Kruger, *Future Med. Chem.*, 2012, **4**, 1527.
- 8 K. L. Seim, A. C. Obermeyer and M. B. Francis, *J. Am. Chem. Soc.*, 2011, **133**, 16970.
- 9 S. D. Tilley and M. B. Francis, *J. Am. Chem. Soc.*, 2006, **128**, 1080.
- 10 T. J. Wadzinski, A. Steinauer, L. Hie, G. Pelletier, A. Schepartz and S. J. Miller, *Nat. Chem.*, 2018, **10**, 644.
- 11 (a) D. W. Romanini and M. B. Francis, *Bioconjugate Chem.*, 2008, **19**, 153; (b) J. M. McFarland, N. S. Joshi and M. B. Francis, *J. Am. Chem. Soc.*, 2008, **130**, 7639; (c) N. S. Joshi, L. R. Whitaker and M. B. Francis, *J. Am. Chem. Soc.*, 2004, **126**, 15942.
- 12 M. W. Jones, G. Mantovani, C. A. Blindauer, S. M. Ryan, X. Wang, D. J. Brayden and D. M. Haddleton, *J. Am. Chem. Soc.*, 2012, **134**, 7406.
- 13 H. Ban, J. Gavriluk and C. F. Barbas III, *J. Am. Chem. Soc.*, 2010, **132**, 1523.
- 14 C. Song, K. Liu, Z. Wang, B. Ding, S. Wang, Y. Weng, C.-W. Chiang and A. Lei, *Chem. Sci.*, 2019, **10**, 7982.
- 15 (a) R. B. Bedford, M. F. Haddow, R. L. Webster and C. J. Mitchell, *Org. Biomol. Chem.*, 2009, **7**, 3119. For an oxidative cross-coupling between two tyrosine residues, see: (b) M. Ben-Lulu, E. Gaster, A. Libman and D. Pappo, *Angew. Chem., Int. Ed.*, 2020, **59**, 4835.
- 16 (a) M. Vilaró, G. Arsequell, G. Valencia, A. Ballesteros and J. Barluenga, *Org. Lett.*, 2008, **10**, 3243; (b) N. Basse, S. Piguel, D. Papapostolou, A. Ferrier-Berthelot, N. Richey, M. Pagano, P. Sarthou, J. Sobczak-Thépot, M. Reboud-Ravaux and J. Vidal, *J. Med. Chem.*, 2007, **50**, 2842.
- 17 (a) Q.-L. Hu, K.-Q. Hou, J. Li, Y. Ge, Z.-D. Song, A. S. C. Chan and X.-F. Xiong, *Chem. Sci.*, 2020, **11**, 6070; (b) Y. Dou, L. J. Kenry, J. Jiang and Q. Zhu, *Chem.-Eur. J.*, 2019, **25**, 6896.
- 18 (a) C. W. Kee, O. Tack, F. Guibbal, T. C. Wilson, P. G. Isenegger, M. Imiolek, S. Verhoog, M. Tilby, G. Boscutti, S. Ashworth, J. Chupin, R. Kashani, A. W. J. Poh, J. K. Sosabowski, S. Macholl, C. Plisson, B. Cornelissen, M. C. Willis, J. Passchier, B. G. Davis and V. Gouverneur, *J. Am. Chem. Soc.*, 2020, **142**, 1180; (b) N. Ichiishi, J. P. Caldwell, M. Lin, W. Zhong, X. Zhu, E. Streckfuss, H.-Y. Kim, C. A. Parish and S. W. Krska, *Chem. Sci.*, 2018, **9**, 4168; (c) K. L. Kirk, M. Nishida, S. Fujii and H. Kimoto, *J. Fluorine Chem.*, 1992, **59**, 197.
- 19 (a) I. Guerrero and A. Correa, *Org. Lett.*, 2020, **22**, 1754; (b) M. San Segundo and A. Correa, *ChemSusChem*, 2018, **11**, 3893; (c) M. San Segundo, I. Guerrero and A. Correa, *Org. Lett.*, 2017, **19**, 5288.
- 20 M. San Segundo and A. Correa, *Chem. Sci.*, 2019, **10**, 8872.
- 21 B. Bhaskararao, S. Singh, M. Anand, P. Verma, P. Prakash, A. C. S. Malakar, H. F. Schaefer and R. B. Sunoj, *Chem. Sci.*, 2020, **11**, 208.
- 22 For selected reviews, see: (a) C. Santiago, N. Sotomayor and E. Lete, *Molecules*, 2020, **25**, 3247; (b) W.-C. Yang, J.-G. Feng, L. Wu and Y.-Q. Zhang, *Adv. Synth. Catal.*, 2019, **361**, 1700; (c) A. Banerjee, Z. Lei and M.-Y. Nga, *Synthesis*, 2019, **51**, 303; (d) X.-F. Wu, *Chem.-Eur. J.*, 2015, **21**, 12252; (e) A. Batra, P. Singh and K. N. Singh, *Eur. J. Org. Chem.*, 2016, 4927; (f) C. Pan, X. Jia and J. Cheng, *Synthesis*, 2012, **44**, 677.
- 23 For selected reviews on the use of DGs in C-H functionalization, see: (a) S. Rej, Y. Ano and N. Chatani, *Chem. Rev.*, 2020, **120**, 1788; (b) C. Sambiagio, D. Schönbauer, R. Blicke, T. Dao-Huy, G. Pototschnig, P. Schaaf, T. Wiesinger, T. F. Zia, J. Wencel-Delord, T. Besset, B. U. W. Maes and M. Schnürch, *Chem. Soc. Rev.*, 2018, **47**, 6603; (c) O. Daugulis, J. Roane and L. D. Tran, *Acc. Chem. Res.*, 2015, **48**, 1053.
- 24 For selected C-H functionalization reactions directed by the 2-pyridyl ether unit on simple phenyl systems, see: (a) S.-J. Lou, Q. Chen, Y.-F. Wang, D.-Q. Xu, X.-H. Du, J.-Q. He, Y.-J. Mao and Z.-Y. Xu, *ACS Catal.*, 2015, **5**, 2846; (b) J.-H. Chu, S.-T. Chen, M.-F. Chiang and M.-J. Wu, *Organometallics*, 2015, **34**, 953; (c) B. Liu, H.-Z. Jiang and B.-F. Shi, *J. Org. Chem.*, 2014, **79**, 1521; (d) J. Yao, R. Feng, Z. Wu, Z. Liu and Y. Zhang, *Adv. Synth. Catal.*, 2013, **355**, 1517; (e) W. Ma and L. Ackermann, *Chem.-Eur. J.*, 2013, **19**, 13925; (f) L. Ackermann, E. Diers and A. Manvar, *Org. Lett.*, 2012, **14**, 1154; (g) X. Jia, S. Zhang, W. Wang, F. Luo and J. Cheng, *Org. Lett.*, 2009, **11**, 3120.
- 25 For more details, see the ESI.†
- 26 (a) M. B. Gawande, V. D. B. Bonifácio, R. Luque, P. S. Branco and R. S. Varma, *Chem. Soc. Rev.*, 2013, **42**, 5522; (b) A. Chanda and V. V. Fokin, *Chem. Rev.*, 2009, **109**, 725; (c) C.-J. Li, *Chem. Rev.*, 2005, **105**, 3095.
- 27 J. Wang, C. Liu, J. Yuan and A. Lei, *Chem. Commun.*, 2014, **50**, 4736.
- 28 (a) Y. Deng, J. Peng, F. Xiong, Y. Song, Y. Zhou, J. Zhang, F. S. Lam, C. Xie, W. Shen, Y. Huang, L. Meng and X. Li,



- Angew. Chem., Int. Ed.*, 2020, **59**, 14965; (b) W.-J. Yoo and C.-J. Li, *J. Am. Chem. Soc.*, 2006, **128**, 13064.
- 29 C.-L. Yi, Y.-T. Huang and C.-F. Lee, *Green Chem.*, 2013, **15**, 2476.
- 30 (a) X. Zeng, Y. Zhang, Z. Liu, S. Geng, Y. He and Z. Geng, *Org. Lett.*, 2020, **22**, 2950; (b) M. Tobisu, J. Zhao, H. Kinuta, T. Furukawa, T. Igarashi and N. Chatani, *Adv. Synth. Catal.*, 2016, **358**, 2417; (c) H. Kinuta, M. Tobisu and N. Chatani, *J. Am. Chem. Soc.*, 2015, **137**, 1593.

